Biologic therapy increases Demodex density in psoriasis patients
International Journal of Dermatology · 2024
DOI: 10.1111/ijd.17161 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Hasan Aksoy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Istanbul Medeniyet University Prof. Dr. Suleyman Yalcin City Hospital, İstanbul, Turkey. Hauptthemen laut MEDLINE: Psoriasis, Mites, Mite Infestations. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Demodex density is known to increase in various immunosuppressive conditions. The relationship between biologic therapy and Demodex density remains unknown. We aimed to investigate whether the density of Demodex mites is higher in psoriasis patients treated with biologic agents compared to treatment‐naive or topically treated patients.
Methods
A cross‐sectional study was conducted, comparing psoriasis patients receiving biologic therapy ( n = 34) with controls ( n = 33). Demodex density was assessed using the standardized skin surface biopsy technique ( SSSB ). Statistical analysis was performed to compare the densities and prevalence of demodicosis between the two groups.
Results
Demodex density was significantly higher in the biologic therapy group compared to the control group on the right cheek (7.29 vs. 0.12/cm 2 ; P = 0.001), left cheek (8.15 vs. 0.24/cm 2 ; P = 0.002), and whole face (average of all four regions: 5.50 vs. 0.80/cm 2 ; P = 0.001). The prevalence of demodicosis was significantly higher in the biologic therapy group on the forehead (35.3% vs. 12.1%; P = 0.043), right cheek (41.2% vs. 0%; P < 0.001), and left cheek (44.1% vs. 0%; P < 0.001). The frequency of cases with demodicosis in at least one localization was higher in the biological therapy group compared to the control group (61.8% vs. 15.2%; P < 0.001).
Conclusions
Psoriasis patients receiving biologic therapy had a higher Demodex density and prevalence of demodicosis compared to controls. Biologics may lead to an increase in Demodex density by blocking specific cytokines, such as interleukin‐17 and tumor necrosis factor‐α, which play a role in immunity against Demodex. Further research is needed to explore the impact of different biological agents on Demodex density.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Istanbul Medeniyet University Prof. Dr. Suleyman Yalcin City Hospital, İstanbul, Turkey.
ORCID-Profile: Hasan Aksoy, Öykü Gönüllü, Melek Aslan Kayıran
Zitieren
APA
Aksoy, H., Altıntaş Kakşi, S., Gönüllü, Ö., Aslan Kayıran, M., & Erdemir, V. A. (2024). Biologic therapy increases Demodex density in psoriasis patients. International Journal of Dermatology. https://doi.org/10.1111/ijd.17161
Vancouver
Aksoy H, Altıntaş Kakşi S, Gönüllü Ö, Aslan Kayıran M, Erdemir VA. Biologic therapy increases Demodex density in psoriasis patients. International Journal of Dermatology. 2024. doi:10.1111/ijd.17161
BibTeX
@article{Aksoy2024,
author = {Aksoy, Hasan and Altıntaş Kakşi, Sümeyye and Gönüllü, Öykü and Aslan Kayıran, Melek and Erdemir, Vefa A},
title = {Biologic therapy increases Demodex density in psoriasis patients},
journal = {International Journal of Dermatology},
year = {2024},
doi = {10.1111/ijd.17161}
}
EUVIMED